Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.97
-0.04 (-0.36%)
At close: May 22, 2026, 4:00 PM EDT
10.99
+0.02 (0.18%)
After-hours: May 22, 2026, 5:28 PM EDT
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
685.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDSGN News
- 6 days ago - Design Therapeutics Transcript: Status update - Transcripts
- 6 days ago - Design Therapeutics Press release: Status update - Filings
- 6 days ago - Design Therapeutics Slides: Status update - Filings
- 7 days ago - Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial - TheFly
- 7 days ago - Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - GlobeNewsWire
- 7 days ago - Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026 - GlobeNewsWire
- 12 days ago - Design Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 13 days ago - Design Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly